Ms-24 * systemic treatment of meningiomas: is there a role for long-acting somatostatin?
CONCLUSION: Long acting somatostatin displays minor activity as salvage treatment for recurrent meningiomas after surgery and radiation therapy. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Soffietti, R., Magistrello, M., Trevisan, E., Bertero, L., Pellerino, A., Ruda, R. Tags: MENINGIOMA/VESTIBULAR SCHWANNOMA/SKULL BASE TUMORS/OTHER (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research
Delayed-Onset Chylous Ascites After a Living-Donor Liver Transplant: First Case Successfully Treated With Conservative Treatment?
We report a case of chylous ascites after a living-donor liver transplant that was diagnosed after 6 months of uneventful follow-up. Sirolimus was added to cyclosporine early (2 wk after the operation) owing to poor renal function and it was found to be high (> 22 ng/mL) when the chylous ascites occurred. The patient was treated with total parenteral nutrition in combination with Sandostatin and rapid tapering of sirolimus after the failed initial conservative treatment. Residual abdominal fullness after meals and lymphedema of the legs disappeared 1 month after discontinuing sirolimus. This is the first case of delayed...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - October 31, 2014 Category: Transplant Surgery Authors: Chen JH, Chang CM, Lu MC, Wei CK, Yin WY Tags: Exp Clin Transplant Source Type: research
1165TiP * NETTER-1: FIRST PIVOTAL PHASE III STUDY EVALUATING 177LU-DOTATATE IN MIDGUT NEUROENDOCRINE TUMOURS
Background: Currently, there is an unmet medical need for long-term effective treatment of inoperable, gastro-entero-pancreatic neuroendocrine tumours (GEPNETs). Patients having midgut neuroendocrine tumours (30-50% of all NETs) have very limited therapeutic options: the only registered products (i.e. somatostatin analogues, such as Octreotide®) are approved for symptomatic treatment, and all other potential treatments are either investigational, or off-label. Tumor-targeted peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate (177Lu-DOTATATE) has been in use since 2000, with over several thous...
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Lopera Sierra, M., Kwekkeboom, D., Mariani, M. F., Bodei, L., Santoro, P., Krenning, E. P. Tags: neuroendocrine & amp; endocrine tumours and cup Source Type: research
Effects of long‐acting somatostatin analogues on redox systems in rat lens in experimental diabetes
Summary
The effects of long‐acting somatostatin analogues, angiopeptin (AGP) and Sandostatin (SMS), on the early decline in the lens content of glutathione (GSH), ATP and NADPH and increase in sorbitol were studied in STZ diabetic rats, and comparison was made with the effect of insulin. Three factors prompted this study: (i) the known increase in IGF‐1 in ocular tissue in diabetes and antagonistic effect of somatostatins, (ii) the known effect of IGF‐1 in increasing lens aldose reductase and (iii) the lack of effect of somatostatins on diabetic hyperglycaemia, the latter enabling a differentiation to be made between...
Source: International Journal of Experimental Pathology - March 6, 2014 Category: Pathology Authors: Sirilaksana Kunjara, A. Leslie Greenbaum, Milena Sochor, Allan Flyvbjerg, Henning Grønbaek, Patricia McLean Tags: Original Article Source Type: research
Recent developments in chemotherapy for meningiomas: a review.
Conclusions Improved understanding of the molecular mechanisms driving meningioma tumorigenesis and malignant transformation has resulted in the targeted development of more specific agents for chemotherapeutic intervention in patients with nonresectable, aggressive, and malignant meningiomas.
PMID: 24289126 [PubMed - in process] (Source: Neurosurgical Focus)
Source: Neurosurgical Focus - December 1, 2013 Category: Neurosurgery Authors: Moazzam AA, Wagle N, Zada G Tags: Neurosurg Focus Source Type: research
Effects of octreotide therapy in progressive head and neck paragangliomas: Case series
ConclusionIn one out of four patients, HNPGL tumor growth velocity was reduced after octreotide therapy. Research assessing the effects of somatostatin analogues targeting different sst subtypes or combined with other therapies may offer new possibilities for the treatment of HNPGLs. Head Neck, 2013 (Source: Head and Neck)
Source: Head and Neck - April 22, 2013 Category: ENT & OMF Authors: L.T. van Hulsteijn, N. van Duinen, B.M. Verbist, J.C. Jansen, A.A. van der Klaauw, J.W.A. Smit, E.P.M. Corssmit Tags: Case Report Source Type: research
Octreotide Acetate Administration for Malignant Bowel Obstruction Induces Severe Bradycardia in Patients with Terminal Stage Cancer: Two Case Reports
Journal of Palliative Medicine , Vol. 0, No. 0. (Source: Journal of Palliative Medicine)
Source: Journal of Palliative Medicine - April 21, 2013 Category: Palliative Care Tags: article Source Type: research
